Literature DB >> 28467472

Effect of dialysis modality on frailty phenotype, disability, and health-related quality of life in maintenance dialysis patients.

Seok Hui Kang1, Jun Young Do1, So-Young Lee2, Jun Chul Kim3.   

Abstract

BACKGROUND: Health-related quality of life (HRQoL) surveys are needed to evaluate regional and ethnic specificies. The aim of the present study was to evaluate the differences in HRQoL, frailty, and disability according to dialysis modality in the Korean population. PATIENTS AND METHODS: We enrolled relatively stable maintenance dialysis patients. A total of 1,616 patients were recruited into our study. The demographic and laboratory data collected at enrollment included age, sex, comorbidities, frailty, disability, and HRQoL scales.
RESULTS: A total of 1,250 and 366 participants underwent hemodialysis (HD) and peritoneal dialysis (PD), respectively. The numbers of participants with pre-frailty and frailty were 578 (46.2%) and 422 (33.8%) in HD patients, and 165 (45.1%) and 137 (37.4%) in PD patients, respectively (P = 0.349). Participants with a disability included 195 (15.6%) HD patients and 109 (29.8%) PD patients (P < 0.001). On multivariate analysis, the mean physical component scale (PCS) and mental component scale (MCS), symptom/problems, and sleep scores were higher in HD patients than in PD patients. Cox regression analyses showed that an increased PCS in both HD and PD patients was positively associated with patient survival and first hospitalization-free survival. An increased MCS in both HD and PD patients was positively associated with first hospitalization-free survival only.
CONCLUSION: There was no significant difference in frailty between patients treated with the two dialysis modalities; however, disability was more common in PD patients than in HD patients. The MCS and PCS were more favorable in HD patients than in PD patients. Symptom/problems, sleep, quality of social interaction, and social support were more favorable in HD patients than in PD patients; however, patient satisfaction and dialysis staff encouragement were more favorable in PD patients than in HD patients.

Entities:  

Mesh:

Year:  2017        PMID: 28467472      PMCID: PMC5415130          DOI: 10.1371/journal.pone.0176814

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Background

Chronic kidney disease is a well-known public health problem that can progress to end-stage renal disease (ESRD), which requires renal replacement therapies such as kidney transplantation, hemodialysis (HD), and peritoneal dialysis (PD). The prevalence of ESRD is approximately 2,034 per million in the US population and 1,571.5 per million in the Korea population [1,2]. Although many interventions can prevent the progression to ESRD, cases of ESRD continue to increase over time, a phenomenon that will continue with increased life expectancy and comorbidities such as diabetes mellitus (DM) and hypertension. Kidney transplantation is the ideal method for treating ESRD patients; however, a lack of kidney donors is the main hurdle for this method. Of all ESRD patients, 70.8% were receiving HD or PD [1]. Frailty is a clinical syndrome that was originally defined by gerontologists to describe cumulative declines across multiple physiological systems [3,4]. However, ESRD patients are inherently at a higher risk of insulin resistance, malnutrition, and inflammation than the general population [5]. These conditions can induce the early development and high prevalence of frailty in dialysis patients. Recent studies have focused on the importance of frailty in dialysis patients; however, few studies have examined the differences in frailty according to dialysis modality [6-8]. The health-related quality of life (HRQoL) of dialysis patients is lower than that of the general population or patients who undergo kidney transplantation, and a low HRQoL is associated with decreased survival and more frequent hospitalization in dialysis patients [9-13]. Proper evaluation of and intervention for HRQoL are important for improving prognosis in dialysis patients. However, there are conflicting results about the association between HRQoL and dialysis modality [10,14-17]. Regional and national disparities may lead researchers to various conclusions concerning the association between HRQoL and dialysis modality. Therefore, HRQoL surveys are needed to evaluate regional and ethnic specificies. Although previous studies have investigated the association between HRQoL and dialysis modality in ESRD patients, few have demonstrated the association between HRQoL and dialysis modality in the Korean populations. The aim of the present study was to evaluate the differences in HRQoL, frailty, and disability according to dialysis modality in the Korean population.

Patients and methods

Study population

The study participants were those enrolled in a previous study [18]. Briefly, the study participants were recruited from 27 hospitals or dialysis centers in Daegu/Kyungsangpook-do between July and December 2012. A total of 2,737 participants who had undergone HD or PD were included. Among these patients, 1,079 were excluded for being <20 years old (n = 12), receiving dialysis for <6 months (n = 164), having a history of hospitalization in the last 3 months except for vascular access problem in HD patients (n = 351), being unable to walk with or without an assistive device (n = 79), being unable to communicate with the interviewer (n = 149), refusing to provide informed consent (n = 254), or not having laboratory findings (n = 112). A total of 1,616 patients were recruited into our study. This study was approved by the institutional review board of Yeungnam University Hospital (2016-06-022).

Study variables

The demographic and laboratory data collected at enrollment included age, sex, body mass index (BMI; kg/m2), DM status, coronary artery disease (CAD), cerebrovascular disease (CVD), dialysis duration (years), dialysis center (tertiary medical center or not), education level, HRQoL scale scores, and hemoglobin (mg/dL), serum albumin (mg/dL), blood urea nitrogen (BUN, mg/dL), creatinine (mg/dL), calcium (mg/dL), phosphorus (mg/dL), total cholesterol (mg/dL), and intact-parathyroid hormone (i-PTH, pg/mL) levels. Serum albumin, BUN, creatinine, calcium, phosphorus, and total cholesterol levels were measured monthly. The values for the 3 months prior to enrollment were averaged. BUN samples were drawn at the midweek treatment. DM was defined as a self-reported history and medical record of DM diagnosis, or a fasting glucose level of ≥126 mg/dL. CAD was defined as a self-reported history and medical record of angina, myocardial infarction, or congestive heart failure. CVD was defined as a self-reported history and medical record of stroke. All mortality and hospitalization events were retrieved from medical records up to December 2014. If a patient with HD was admitted for a vascular access–related problem, the event was not considered a significant hospitalization.

HRQoL assessment

HRQoL was assessed by using the Kidney Disease Quality of Life-Short Form (KDQOL–SF) 1.3 Korean version [19]. KDQOL–SF 1.3 includes the SF-36 scale (36 items) and a kidney disease–specific scale (11 items). SF-36 includes eight domains–physical functioning (PF), role limitations due to physical health problems (RP), body pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH)–and the overall health rating (OHR). A total score of 0–100 was calculated for each domain. A low score indicates a low quality of life. These tools were used to calculate two summary scales: a physical component scale (PCS) and a mental component scale (MCS) [20,21]. The 11 kidney disease-specific items consisted of symptom/problems, effects of kidney disease, burden of kidney disease, work status, cognitive function, quality of social interaction, sexual function, sleep, social support, patient satisfaction, and dialysis staff encouragement.

Frailty phenotype and disability assessments

We evaluated disability by using four questions on activities of daily living (ADLs) concerning whether the participants currently need help from another person in feeding, dressing/undressing, getting in/out of bed, or taking a bath/shower. For each question, they participants provided one of three responses: no help, some help, or full help. Disability was defined as the inability to perform at least one of the four ADL domains with no help [22]. We scored each ADL as requiring no help (0), some help (1), or full help (2). We also defined the total disability score as the sum of the individual ADL scores. Frailty was defined by using previously described modified criteria [23]. Briefly, the components consisted of slowness/weakness, poor endurance/exhaustion, physical inactivity, and unintentional weight loss. Slowness/weakness and poor endurance/exhaustion were determined by using the PF scale (2 points for PF scale <75) and the VT scale (1 point for VT scale <55) of SF-36, respectively. Physical inactivity was defined as being physically active <1 time per week during leisure time for the last 3 months (1 point for physical inactivity). Unintentional weight loss was defined as an unintentional body weight loss of > 4.5 kg or 5% of the baseline value during the last year (1 point for weight loss). All points of each frailty component were summed. Those participants with ≥ 3 points, 1 or 2 points, and 0 points were defined as having frailty, pre-frailty, and non-frailty, respectively.

Statistical analyses

The data were analyzed by using the statistical software SPSS version 21 (SPSS Inc., Chicago, IL, USA). Categorical variables are expressed as both counts and percentages. Continuous variables are expressed as mean ± standard deviation or mean ± standard error (SE). Pearson’s χ2 or Fisher’s exact test was used to analyze categorical variables. For continuous variables, means were compared by using Student’s t-test or analysis of variance, followed by a post-hoc Tukey comparison. A linear regression analysis was performed to assess the independent predictors of the HRQoL scales. The survival estimates were calculated by using Kaplan–Meier with the log-rank test and Cox regression analyses. Multivariate analysis was performed by using analysis of covariance, multivariate linear regression analysis, or multivariate Cox regression analysis. For the analysis of covariance and linear regression analysis, the covariates were age, sex, BMI, education level, dialysis duration, DM, CVD, CAD, serum albumin level, BUN level, serum creatinine level, i-PTH level, and total cholesterol level. Multivariate Cox regression analyses were performed by using enter mode with adjustment for age, sex, BMI, education level, dialysis duration, DM, CVD, CAD, serum albumin level, BUN level, serum creatinine level, i-PTH level, and total cholesterol level. The level of statistical significance was set at P < 0.05.

Results

Participants’ clinical characteristics

A total of 1,250 and 366 participants underwent HD and PD, respectively (Table 1). Age and hemoglobin, serum albumin, and BUN levels were higher in HD patients than in PD patients. BMI and serum creatinine, total cholesterol, and i-PTH levels were higher in PD patients than in HD patients. A greater proportion of HD patients than PD patients had DM, CAD, or CVD, whereas the proportion of male sex, the education levels, and the calcium and phosphorus levels were similar between the two groups.
Table 1

Participants’ clinical characteristics.

Hemodialysis (n = 1,250)Peritoneal dialysis (n = 366)P-value*
Age (years)56.4 ± 13.254.1 ± 11.90.003
Male sex (%)708 (56.6%)195 (53.3%)0.255
Body mass index (kg/m2)22.1 ± 3.223.5 ± 3.1<0.001
Diabetes mellitus (%)516 (41.3%)123 (33.6%)0.008
Coronary artery disease (%)221 (17.7%)33 (9.0%)<0.001
Cerebrovascular disease (%)129 (10.3%)15 (4.1%)<0.001
Tertiary center (%)525 (42.0%)359 (97.3%)<0.001
Dialysis vintage (years)5.1 ± 4.65.3 ± 3.90.409
Education level0.121
 ≤ 6th grade285 (22.8%)69 (18.9%)
 7th–12th grade253 (20.2%)67 (18.3%)
 > 12th grade712 (57.0%)230 (62.8%)
Hemoglobin (mg/dL)10.5 ± 0.810.4 ± 1.10.016
Serum albumin (mg/dL)4.0 ± 0.33.6 ± 0.4<0.001
Blood urea nitrogen (mg/dL)61.9 ± 14.353.5 ± 15.5<0.001
Creatinine (mg/dL)10.3 ± 2.811.1 ± 3.6<0.001
Calcium (mg/dL)8.7 ± 0.88.6 ± 0.90.060
Phosphorus (mg/dL)5.3 ± 1.45.3 ± 1.30.645
Total cholesterol (mg/dL)148.6 ± 35.3172.5 ± 38.0<0.001
Intact parathyroid hormone (pg/mL)264.9 ± 309.2319.6 ± 433.90.007

Data are expressed as number (percentage) for categorical variables and mean ± standard deviation for continuous variables.

* P-values were tested by using Student’s t-test for continuous variables and Pearson’s χ2 test or Fisher’s exact test for categorical variables.

Data are expressed as number (percentage) for categorical variables and mean ± standard deviation for continuous variables. * P-values were tested by using Student’s t-test for continuous variables and Pearson’s χ2 test or Fisher’s exact test for categorical variables.

Comparison of frailty and disability according to dialysis modality

The numbers of participants with pre-frailty and frailty were 578 (46.2%) and 422 (33.8%) in HD patients, and 165 (45.1%) and 137 (37.4%) in PD patients, respectively (P = 0.349). The total frailty score (mean ± SE) was 1.89 ± 0.04 in HD patients and 1.96 ± 0.08 in PD patients (P = 0.433). Among individual components, the scores for slowness/weakness, poor endurance/exhaustion, physical inactivity, and unintentional weight loss were 0.67 ± 0.03, 0.66 ± 0.03, 0.45 ± 0.01, and 0.11 ± 0.01 in HD patients and 0.77 ± 0.05, 0.68 ± 0.02, 0.44 ± 0.03, and 0.07 ± 0.01 in PD patients, respectively (P = 0.087 for slowness/weakness; P = 0.495 for poor endurance/exhaustion; P = 0.702 for physical inactivity; P = 0.042 for unintentional weight loss). Multivariate analyses showed that the total frailty score was 1.89 ± 0.04 in HD patients and 1.97 ± 0.09 in PD patients (P = 0.445). The scores for slowness/weakness, poor endurance/exhaustion, physical inactivity, and unintentional weight loss were 0.67 ± 0.03, 0.66 ± 0.01, 0.45 ± 0.02, and 0.12 ± 0.01 in HD patients and 0.80 ± 0.05, 0.68 ± 0.03, 0.44 ± 0.03, and 0.06 ± 0.02 in PD patients, respectively (P = 0.036 for slowness/weakness; P = 0.634 for poor endurance/exhaustion; P = 0.650 for physical inactivity; P = 0.010 for unintentional weight loss). In a comparison with HD patients, multivariate analyses showed that PD patients had an odds ratio of 1.298 (95% confidence interval [CI], 0.936–1.800; P = 0.118) for frailty. Participants with a disability included 195 (15.6%) HD patients and 109 (29.8%) PD patients (P < 0.001). The number of disabilities (mean ± SE) was 0.30 ± 0.02 in the HD group and 0.52 ± 0.05 in the PD group (P < 0.001). The total disability score was 0.37 ± 0.03 in HD patients and 0.63 ± 0.07 in PD patients (P < 0.001). Among individual components, the scores for feeding, dressing/undressing, getting in/out of bed, and taking a bath/shower were 0.07 ± 0.01, 0.07 ± 0.01, 0.07 ± 0.01, and 0.16 ± 0.01 in HD patients and 0.15 ± 0.03, 0.10 ± 0.02, 0.09 ± 0.02, and 0.30 ± 0.03 in PD patients, respectively (P = 0.002 for feeding; P = 0.216 for dressing/undressing; P = 0.312 for getting in/out of bed; P < 0.001 for taking a bath/shower). Multivariate analyses showed that the number of disabilities was 0.29 ± 0.03 in the HD group and 0.56 ± 0.05 in the PD group (P < 0.001). The total disability score was 0.37 ± 0.04 in HD patients and 0.66 ± 0.07 in PD patients (P = 0.001). Among individual components, the scores for feeding, dressing/undressing, getting in/out of bed, and taking a bath/shower were 0.07 ± 0.01, 0.07 ± 0.01, 0.07 ± 0.01, and 0.15 ± 0.01 in HD patients and 0.15 ± 0.03, 0.11 ± 0.02, 0.09 ± 0.02, and 0.32 ± 0.03 in PD patients, respectively (P = 0.012 for feeding; P = 0.230 for dressing/undressing; P = 0.233 for getting in/out of bed; P < 0.001 for taking a bath/shower). In a comparison with HD patients, multivariate analyses showed that PD patients had an odds ratio of 3.013 (95% CI, 2.076–4.373; P = 0.118) for disability. There was no significant difference in frailty phenotype between HD and PD patients; however, the score for slowness/weakness was higher in PD patients than in HD patients, and the score for unintentional weight loss was higher in HD patients than in PD patients. Disability was more common in PD patients than in HD patients. The scores for feeding and taking a bath/shower were higher in PD patients than in HD patients.

Comparison of HRQoL scale scores according to dialysis modality

Table 2 shows the differences in HRQoL scale scores according to dialysis modality. On univariate analysis, the mean RE, OHR, PCS, MCS, symptom/problems, and quality of social interaction scores were higher in HD patients than in PD patients, whereas the mean patient satisfaction and dialysis staff encouragement scores were higher in PD patients than in HD patients. On multivariate analysis, the mean PF, GH, SF, RE, OHR, PCS, MCS, symptom/problems, and sleep scores were higher in HD patients than in PD patients.
Table 2

Comparison of quality-of-life scales between hemodialysis patients and peritoneal dialysis patients.

Univariate (mean ± SD)Multivariate (mean ± SE)
Short Form-36 scaleHDPDP-valueHDPDP-value
PF74.8 ± 24.172.3 ± 22.80.08275.0 ± 0.671.6 ± 1.30.028
RP65.7 ± 41.561.4 ± 41.10.08366.0 ± 1.260.3 ± 2.60.060
BP77.9 ± 25.776.1 ± 24.70.21678.1 ± 0.775.4 ± 1.60.137
GH45.2 ± 22.941.6 ± 20.70.00845.3 ± 0.741.1 ± 1.40.010
VT44.8 ± 21.544.4 ± 20.40.74144.9 ± 0.744.2 ± 1.30.646
SF76.1 ± 28.173.1 ± 26.50.07276.6 ± 0.871.6 ± 1.70.016
RE72.7 ± 41.164.8 ± 43.00.00173.2 ± 1.262.9 ± 2.60.001
MH59.1 ± 20.458.2 ± 20.40.45859.2 ± 0.658.0 ± 1.30.418
OHR38.6 ± 26.333.9 ± 24.50.00338.6 ± 0.833.9 ± 1.60.015
PCS61.7 ± 20.759.2 ± 20.00.04061.9 ± 0.658.5 ± 1.20.022
MCS59.6 ± 20.656.4 ± 20.00.01059.8 ± 0.655.5 ± 1.30.004
KD-specific scale
Symptom/problems80.9 ± 14.577.9 ± 16.20.00183.8 ± 0.878.8 ± 1.80.019
Effects of KD72.5 ± 19.374.6 ± 18.90.06774.6 ± 1.076.1 ± 2.30.594
Burden of KD34.6 ± 26.536.6 ± 26.20.21339.1 ± 1.537.0 ± 3.40.591
Work status27.8 ± 36.028.0 ± 37.20.93938.5 ± 2.349.1 ± 5.20.081
Cognitive function86.2 ± 17.485.4 ± 17.40.43690.3 ± 0.886.3 ± 1.90.071
Quality of social interaction76.2 ± 21.872.4 ± 21.60.00379.6 ± 1.274.4 ± 2.70.103
Sexual function78.0 ± 26.075.3 ± 26.70.42078.6 ± 1.572.5 ± 3.50.131
Sleep64.2 ± 21.562.2 ± 20.90.43868.5 ± 1.262.1 ± 2.70.044
Social support68.4 ± 27.065.6 ± 27.10.08070.2 ± 1.564.6 ± 3.60.176
Patient satisfaction64.6 ± 22.770.0 ± 23.0<0.00167.3 ± 1.466.3 ± 3.10.794
DSE85.1 ± 19.090.2 ± 15.9<0.00186.8 ± 1.089.1 ± 2.40.408

P-values were tested by using Student’s t-test for univariate analysis and analysis of covariance for multivariate analysis. The multivariate analysis was adjusted for age, sex, body mass index, education level, dialysis duration, diabetes mellitus, cerebrovascular disease, coronary artery disease, serum albumin level, blood urea nitrogen level, serum creatinine level, intact-parathyroid hormone level, and total cholesterol level.

Abbreviations: SD, standard deviation; SE, standard error; HD, hemodialysis; PD, peritoneal dialysis; PF, physical functioning; RP, role limitations due to physical health problems; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role limitations due to emotional problems; MH, mental health; OHR, overall health rating; PCS, physical component scale; MCS, mental component scale; KD, kidney disease; DSE, dialysis staff encouragement.

P-values were tested by using Student’s t-test for univariate analysis and analysis of covariance for multivariate analysis. The multivariate analysis was adjusted for age, sex, body mass index, education level, dialysis duration, diabetes mellitus, cerebrovascular disease, coronary artery disease, serum albumin level, blood urea nitrogen level, serum creatinine level, intact-parathyroid hormone level, and total cholesterol level. Abbreviations: SD, standard deviation; SE, standard error; HD, hemodialysis; PD, peritoneal dialysis; PF, physical functioning; RP, role limitations due to physical health problems; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role limitations due to emotional problems; MH, mental health; OHR, overall health rating; PCS, physical component scale; MCS, mental component scale; KD, kidney disease; DSE, dialysis staff encouragement. Linear regression analysis showed that, on univariate analysis, PD was inversely associated with GH, RE, OHR, PCS, MCS, symptom/problems, and quality of social interaction, and positively associated with patient satisfaction and dialysis staff encouragement (Table 3). Multivariate analysis showed an inverse association between PD and PF, GH, SF, RE, OHR, PCS, MCS, symptom/problems, cognitive function, quality of social interaction, and social support. Positive associations were observed between PD and patient satisfaction or dialysis staff encouragement.
Table 3

Linear regression analysis of HRQoL scales in PD and HD patients.

UnivariateMultivariate
Short Form-36 scaleβ ± SEP-valueβ ± SEP-value*
PF–2.458 ± 1.4140.082–3.381 ± 1.5400.028
RP–4.261 ± 2.4600.083–5.691 ± 3.0280.060
BP–1.874 ± 1.5150.216–2.754 ± 1.8500.137
GH–3.540 ± 1.3350.008–4.284 ± 1.6510.010
VT–0.417 ± 1.2630.741–0.708 ± 1.5410.646
SF–2.975 ± 1.6510.072–4.945 ± 2.0440.016
RE–7.879 ± 2.4680.001–10.276 ± 3.0610.001
MH–0.901 ± 1.2130.458–1.217 ± 1.5010.418
OHR–4.665 ± 1.5410.003–4.637 ± 1.8990.015
PCS–2.510 ± 1.2160.040–3.363 ± 1.4950.022
MCS–3.142 ± 1.2230.010–4.286 ± 1.4630.004
KD-targeted scale
Symptom/problems–2.984 ± 0.8850.001–4.104 ± 1.0950.000
Effects of KD2.090 ± 1.1390.067–0.639 ± 1.4080.650
Burden of KD1.954 ± 1.5690.2130.018 ± 1.9360.993
Work status0.165 ± 2.1550.9392.320 ± 2.5120.356
Cognitive function–0.806 ± 1.0340.436–3.537 ± 1.2650.005
Quality of social interaction–3.781 ± 1.2920.003–5.116 ± 1.5970.001
Sexual function–2.686 ± 3.3280.420–6.138 ± 4.0850.131
Sleep–0.983 ± 1.2690.438–2.660 ± 1.5780.092
Social support–2.815 ± 1.6070.080–4.789 ± 2.0000.017
Patient satisfaction5.464 ± 1.7520.0004.322 ± 1.6760.010
DSE5.078 ± 1.0880.0004.568 ± 1.3440.001

* A multivariate model analysis was performed by using age, sex, body mass index, education level, dialysis vintage, diabetes mellitus, cerebrovascular disease, coronary artery disease, serum albumin level, blood urea nitrogen level, serum creatinine level, intact-parathyroid hormone level, and total cholesterol level. β was calculated as peritoneal dialysis compared with hemodialysis. Each scale in the HRQoL was a dependent variable.

Abbreviations: HRQoL, health-related quality of life; PD, peritoneal dialysis; HD, hemodialysis; β, unstandardized coefficient; PF, physical functioning; RP, role limitations due to physical health problems; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role limitations due to emotional problems; MH, mental health; OHR, overall health rating; PCS, physical component scale; MCS, mental component scale; KD, kidney disease; DSE, dialysis staff encouragement.

* A multivariate model analysis was performed by using age, sex, body mass index, education level, dialysis vintage, diabetes mellitus, cerebrovascular disease, coronary artery disease, serum albumin level, blood urea nitrogen level, serum creatinine level, intact-parathyroid hormone level, and total cholesterol level. β was calculated as peritoneal dialysis compared with hemodialysis. Each scale in the HRQoL was a dependent variable. Abbreviations: HRQoL, health-related quality of life; PD, peritoneal dialysis; HD, hemodialysis; β, unstandardized coefficient; PF, physical functioning; RP, role limitations due to physical health problems; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role limitations due to emotional problems; MH, mental health; OHR, overall health rating; PCS, physical component scale; MCS, mental component scale; KD, kidney disease; DSE, dialysis staff encouragement. Most PD patients were followed at tertiary dialysis centers (97.3%), and we analyzed differences in HRQoL scales according to these groups: tertiary HD patients, non-tertiary HD patients, and tertiary PD patients (S1 Table). Among the three groups, tertiary PD patients had lower mean GH and MCS scores than tertiary HD patients. In addition, tertiary PD patients had the lowest scores for RE, OHR, symptom/problems, and quality of social interaction but the highest scores for dialysis staff encouragement. Tertiary HD patients had the lowest work status scores but the highest social support scores, whereas non-tertiary HD patients had the lowest patient satisfaction scores.

Clinical outcomes according to HRQoL scales

The follow-up durations (mean ± SD) in HD and PD patients were 489 ± 116 and 467 ± 104 days, respectively. The number of deaths during follow-up was 61 (4.9%) in HD patients and 25 (6.8%) in PD patients. The numbers of participants hospitalized during follow-up was 415 (33.2%) in HD patients and 181 (49.5%) in PD patients. The participants were divided into three groups based on the tertile values for MCS or PCS. Kaplan–Meier analyses showed that both HD and PD patients with a low tertile for PCS had poor patient survival and poor first hospitalization-free survival (Fig 1A–1D). Both HD and PD patients with a low tertile for MCS had poor first hospitalization–free survival (Fig 2A–2D).
Fig 1

Kaplan-Meier curves of patient survival (A, hemodialysis; B, peritoneal dialysis) and hospitalization-free survival (C, hemodialysis; D, peritoneal dialysis) among the physical component summary score tertiles.

(A) Survival rate of hemodialysis patients (High tertile: 99.5% at 100 days and 97.6% at 500 days; Middle tertile: 99.8% at 100 days and 95.0% at 500 days; Low tertile: 99.8% at 100 days and 92.3% at 500 days; P = 0.004). (B) Survival rate of peritoneal dialysis patients (High tertile: 100% at 100 days and 97.1% at 500 days; Middle tertile: 100% at 100 days and 95.2% at 500 days; Low tertile: 99.2% at 100 days and 87.2% at 500 days; P = 0.024). (C) Hospitalization-free survival rate of hemodialysis patients (High tertile: 94.5% at 100 days and 77.1% at 500 days; Middle tertile: 93.2% at 100 days and 66.9% at 500 days; Low tertile: 86.0% at 100 days and 54.8% at 500 days; P < 0.001). (D) Hospitalization-free survival rate of peritoneal dialysis patients (High tertile: 93.0% at 100 days and 62.8% at 500 days; Middle tertile: 87.6% at 100 days and 43.9% at 500 days; Low tertile: 75.2% at 100 days and 43.1% at 500 days; P = 0.003).

Fig 2

Kaplan-Meier curves for patient survival (A, hemodialysis; B, peritoneal dialysis) and hospitalization-free survival (C, hemodialysis; D, peritoneal dialysis) among the mental component summary score tertiles.

(A) Survival rate of hemodialysis patients (High tertile: 99.5% at 100 days and 96.2% at 500 days; Middle tertile: 99.8% at 100 days and 95.2% at 500 days; Low tertile: 99.8% at 100 days and 93.3% at 500 days; P = 0.101). (B) Survival rate of peritoneal dialysis patients (High tertile: 100% at 100 days and 96.3% at 500 days; Middle tertile: 100% at 100 days and 92.3% at 500 days; Low tertile: 99.2% at 100 days and 90.9% at 500 days; P = 0.169). (C) Hospitalization-free survival rate of hemodialysis patients (High tertile: 94.1% at 100 days and 74.5% at 500 days; Middle tertile: 91.5% at 100 days and 64.0% at 500 days; Low tertile: 88.0% at 100 days and 59.5% at 500 days; P < 0.001). (D) Hospitalization-free survival rate of peritoneal dialysis patients (High tertile: 90.0% at 100 days and 59.4% at 500 days; Middle tertile: 88.7% at 100 days and 50.6% at 500 days; Low tertile: 76.9% at 100 days and 38.8% at 500 days; P = 0.003).

Kaplan-Meier curves of patient survival (A, hemodialysis; B, peritoneal dialysis) and hospitalization-free survival (C, hemodialysis; D, peritoneal dialysis) among the physical component summary score tertiles.

(A) Survival rate of hemodialysis patients (High tertile: 99.5% at 100 days and 97.6% at 500 days; Middle tertile: 99.8% at 100 days and 95.0% at 500 days; Low tertile: 99.8% at 100 days and 92.3% at 500 days; P = 0.004). (B) Survival rate of peritoneal dialysis patients (High tertile: 100% at 100 days and 97.1% at 500 days; Middle tertile: 100% at 100 days and 95.2% at 500 days; Low tertile: 99.2% at 100 days and 87.2% at 500 days; P = 0.024). (C) Hospitalization-free survival rate of hemodialysis patients (High tertile: 94.5% at 100 days and 77.1% at 500 days; Middle tertile: 93.2% at 100 days and 66.9% at 500 days; Low tertile: 86.0% at 100 days and 54.8% at 500 days; P < 0.001). (D) Hospitalization-free survival rate of peritoneal dialysis patients (High tertile: 93.0% at 100 days and 62.8% at 500 days; Middle tertile: 87.6% at 100 days and 43.9% at 500 days; Low tertile: 75.2% at 100 days and 43.1% at 500 days; P = 0.003).

Kaplan-Meier curves for patient survival (A, hemodialysis; B, peritoneal dialysis) and hospitalization-free survival (C, hemodialysis; D, peritoneal dialysis) among the mental component summary score tertiles.

(A) Survival rate of hemodialysis patients (High tertile: 99.5% at 100 days and 96.2% at 500 days; Middle tertile: 99.8% at 100 days and 95.2% at 500 days; Low tertile: 99.8% at 100 days and 93.3% at 500 days; P = 0.101). (B) Survival rate of peritoneal dialysis patients (High tertile: 100% at 100 days and 96.3% at 500 days; Middle tertile: 100% at 100 days and 92.3% at 500 days; Low tertile: 99.2% at 100 days and 90.9% at 500 days; P = 0.169). (C) Hospitalization-free survival rate of hemodialysis patients (High tertile: 94.1% at 100 days and 74.5% at 500 days; Middle tertile: 91.5% at 100 days and 64.0% at 500 days; Low tertile: 88.0% at 100 days and 59.5% at 500 days; P < 0.001). (D) Hospitalization-free survival rate of peritoneal dialysis patients (High tertile: 90.0% at 100 days and 59.4% at 500 days; Middle tertile: 88.7% at 100 days and 50.6% at 500 days; Low tertile: 76.9% at 100 days and 38.8% at 500 days; P = 0.003). Univariate Cox regression analysis showed that an increased PCS in both HD and PD patients was positively associated with patient survival and first hospitalization–free survival (Table 4). An increased MCS in both HD and PD patients was positively associated with first hospitalization–free survival only. Multivariate Cox regression analysis showed that an increased PCS or MCS in HD patients was positively associated with first hospitalization–free survival only. However, an increased PCS or MCS in PD patients was positively associated with patient survival and first hospitalization–free survival.
Table 4

Cox regression analyses according to quality-of-life scale scores.

UnivariateMultivariate
Patient survivalHazard ratio (95% CI)P-valueHazard ratio (95% CI)P-value
HD
 PCS0.982 (0.971–0.993)0.0010.989 (0.977–1.000)0.055
 MCS0.992 (0.981–1.004)0.1730.996 (0.984–1.008)0.492
PD
 PCS0.972 (0.955–0.990)0.0020.975 (0.956–0.995)0.016
 MCS0.982 (0.964–1.000)0.0540.978 (0.958–0.999)0.037
First HFS
HD
 PCS0.984 (0.980–0.989)0.0000.998 (0.983–0.992)0.000
 MCS0.990 (0.986–0.994)0.0000.992 (0.987–0.997)0.001
PD
 PCS0.984 (0.977–0.991)0.0000.987 (0.979–0.994)0.001
 MCS0.988 (0.980–0.995)0.0010.987 (0.980–0.994)0.001

Multivariate analysis was performed by using enter mode with adjustment for age, sex, body mass index, education level, dialysis vintage, diabetes mellitus, cerebrovascular disease, coronary artery disease, serum albumin level, blood urea nitrogen level, serum creatinine level, intact parathyroid hormone level, and total cholesterol level.

Abbreviations: CI, confidence interval; HD, hemodialysis; PCS, physical component scale; MCS, mental component scale; HFS, hospitalization-free survival.

Multivariate analysis was performed by using enter mode with adjustment for age, sex, body mass index, education level, dialysis vintage, diabetes mellitus, cerebrovascular disease, coronary artery disease, serum albumin level, blood urea nitrogen level, serum creatinine level, intact parathyroid hormone level, and total cholesterol level. Abbreviations: CI, confidence interval; HD, hemodialysis; PCS, physical component scale; MCS, mental component scale; HFS, hospitalization-free survival.

Clinical outcomes according to frailty and disability

In HD patients, univariate and multivariate Cox regression analyses showed that the presence of frailty or disability was inversely associated with patient survival and first hospitalization-free survival (Table 5). In PD patients, the presence of frailty was inversely associated with first hospitalization-free survival in both univariate and multivariate analyses. The presence of disability was inversely associated with patient survival only in univariate analysis.
Table 5

Cox regression analyses according to frailty or disability.

UnivariateMultivariate
Patient survivalHazard ratio (95% CI)P-valueHazard ratio (95% CI)P-value
HD
 Frailty3.069 (1.836–5.130)0.0002.352 (1.364–4.056)0.002
 Disability2.940 (1.733–4.988)0.0002.136 (1.206–3.783)0.009
PD
 Frailty2.654 (1.192–5.910)0.0171.754 (0.683–4.499)0.243
 Disability1.391 (0.615–3.148)0.4280.974 (0.401–2.363)0.953
First HFS
HD
 Frailty1.871 (1.541–2.271)0.0001.558 (1.265–1.919)0.000
 Disability1.712 (1.354–2.165)0.0001.431 (1.116–1.836)0.005
PD
 Frailty1.782 (1.330–2.389)0.0001.405 (1.017–1.940)0.039
 Disability1.284 (0.941–1.753)0.1151.160 (0.837–1.606)0.372

Multivariate analysis was performed by using enter mode with adjustment for age, sex, body mass index, education level, dialysis vintage, diabetes mellitus, cerebrovascular disease, coronary artery disease, serum albumin level, blood urea nitrogen level, serum creatinine level, intact parathyroid hormone level, and total cholesterol level. Abbreviations: CI, confidence interval; HD, hemodialysis; PCS, physical component scale; MCS, mental component scale; HFS, hospitalization-free survival.

Multivariate analysis was performed by using enter mode with adjustment for age, sex, body mass index, education level, dialysis vintage, diabetes mellitus, cerebrovascular disease, coronary artery disease, serum albumin level, blood urea nitrogen level, serum creatinine level, intact parathyroid hormone level, and total cholesterol level. Abbreviations: CI, confidence interval; HD, hemodialysis; PCS, physical component scale; MCS, mental component scale; HFS, hospitalization-free survival.

Discussion

Our study included only relatively stable maintenance dialysis patients. There was no significant difference in frailty phenotypes between the two modalities; however, disability was more common in PD patients than in HD patients. MCS and PCS were more favorable in HD patients than in PD patients. Among the kidney disease–specific scales, symptom/problems, sleep, quality of social interaction, and social support were more favorable in HD patients than in PD patients, whereas patient satisfaction and dialysis staff encouragement were more favorable in PD patients than in HD patients. PCS was associated with patient survival and hospitalization, whereas MCS was associated with hospitalization only. Although many studies showed similar HRQoL results between HD and PD patients, some studies showed better outcomes in HD patients. Wu et al. investigated the difference in HRQoL between HD and PD patients [24]. They evaluated the HRQoL at baseline and at 1 year after dialysis initiation. The HRQoL scale scores were similar between the two modalities; however, the HRQoL improvement during the 1-year period was greater in HD patients than in PD patients. A study in Brazil showed that the functional capacity, physical aspect, and social aspect were better in HD patients than in PD patients [10]. A review that included 26 studies showed that the baseline HRQoL scale scores were mostly higher in PD patients than in HD patients [25]. However, the follow-up mental health scale scores were comparable between the two modalities, and the follow-up physical scale scores were relatively better in HD patients than in PD patients. In our study, four scales among eight items in SF-36, the OHR, the PCS, and the MCS were better in HD patients than in PD patients. Symptom/problems, sleep, quality of social interaction, and social support among kidney disease-specific items were better in HD patients than in PD patients. In Korea, the proportions of patients undergoing HD, kidney transplantation, and PD in 2014 were 71.0%, 19.8%, and 9.2%, respectively [2]. PD is mostly offered only at tertiary centers, whereas HD is offered in both tertiary and non-tertiary centers [2]. Therefore, HD is considered the first choice among renal replacement therapies in most centers. In Korea, when ESRD patients have contraindications for HD, such as poor vascular status, intractable intradialytic hypotension, or a preference for PD, PD may be recommended. In addition, in our study, all the tertiary centers were located within the Daegu metropolitan area, whereas the HD centers were distributed between both the Daegu metropolitan area and Kyungsangpook-do. Thus, some PD patients must travel to another area to visit the hospital. These points may be associated with the favorable SF-36 results of the HD patients. In the present study, the scale scores for dialysis care–related patient satisfaction and dialysis staff encouragement were higher in PD patients than in HD patients. These results were similar to those of previous studies [17,26-29]. PD patients were mostly followed at tertiary centers, which may provide more information about the different modalities. In addition, PD patients were three times more likely to switch to HD, often for various causes, whereas dialysis staff in tertiary centers may encourage patients to maintain their current modality [30]. These factors may be associated with the increased scores of PD patients in patient satisfaction and dialysis staff encouragement. Juergensen et al. showed that PD patients were more satisfied with their overall care and perceived less disturbance in their lives than did HD patients [27]. A national multicenter study compared patient satisfaction by using three overall ratings and 20 items rating specific aspects of dialysis care between HD and PD [28]. All ratings or items were greater in PD patients than in HD patients. A previous study with KDQOL–SF 1.3 also showed better patient satisfaction and dialysis staff encouragement in PD patients than in HD patients; however, statistical significance was only observed in patient satisfaction [29]. The association between HRQoL and clinical outcomes in HD patients is well-known [11-13]. Another study investigated the association between the two variables in ESRD patients but did not perform subgroup analysis according to dialysis modality [31]. Other studies evaluated the association between the two variables in PD patients but used only SF-36 items [32,33]. The present study investigated KDQOL–SF including kidney disease–specific items and performed subgroup analyses of each dialysis modality. In our study, PCS was associated with patient survival and hospitalization, but MCS was associated with hospitalization only. We enrolled relatively stable maintenance dialysis patients with a high survival rate. Concerning the shape of the Kaplan–Meier curve, long-term follow-up may result in statistical significance. In our study, the differences in frailty and disability between the two dialysis modalities are important findings. Disability is closely associated with frailty; however, the present study showed no significant difference in frailty phenotype between the two modalities; however, the presence and number of disability components were higher in PD patients than in HD patients. These results reveal that a greater proportion of PD patients than HD patients had a disability regardless of physical functional status. Disability is defined as difficulty with ADLs, which are mainly performed outside of the dialysis period. PD patients receive the dialysate during an entire day, which can lead to disability. If the peritoneal dialysate is associated with disability, night intermittent PD may improve this problem. In our study, the type of PD was not evaluated; however, <20% of total PD patients in Korea receive automated PD [34]. Most PD patients in our study mainly received continuous ambulatory PD. The BMI, serum albumin level, and serum creatinine level, which are well-known nutritional markers, differed between HD and PD patients in our study. In ESRD patients, malnutrition is closely associated with sarcopenia and quality of life, and these differences can indirectly influence HRQoL or frailty. In the present study, BMI was greater in PD patients than in HD patients, but serum albumin level was greater in HD patients than in PD patients. However, the differences in these two variables can be associated with overhydration. PD patients are generally overhydrated compared with HD patients [35]. An overhydrated volume status leads to overestimation of body weight, which results in increased BMI, and dilution of serum albumin, which results in a decreased serum albumin level [36]. In addition, the serum creatinine level was greater in PD patients than in HD patients. Serum creatinine is another classic marker of muscle mass in the general population; however, the association between serum creatinine level and muscle mass is very complex in ESRD patients. Serum creatinine levels are dependent on various factors such as age, sex, race, residual renal function, dialysis adequacy, and comorbidities. The association between these variables and nutritional status should be carefully interpreted in ESRD patients, as a previous study showed no association between serum creatinine level and muscle mass [37]. To overcome these differences, we analyzed HRQoL or disability by using multivariate analyses adjusted to these variables, and our results showed that the dialysis modality is associated with the HRQoL scales. Frailty, disability, and PCS would be interchangeably to identify decreased physical functional status, but they are distinct clinical entities. These three concepts can influence each other. The associations among these indicators are very complex and it is difficult to identify causal relationships. It may be difficult to identify superiority among these measurements, but, for specific populations or outcomes, one may be superior to the others. Our study showed that in HD patients, PCS was only positively associated with first hospitalization–free survival, but the presence of frailty or disability was inversely associated with both patient survival and first hospitalization-free survival. In PD patients, PCS was positively associated with both patient survival and first hospitalization–free survival. However, the presence of frailty was only inversely associated with first hospitalization-free survival, and the presence of disability was not associated with the two clinical outcomes. Our results revealed that the predictive value of frailty or disability for clinical outcomes may be superior to that of PCS in HD patients, and the predictive value of PCS for clinical outcomes may be superior to that of frailty or disability in PD patients. Further investigation is needed to identify superiority among these measurements in dialysis patients. The present study has a few limitations. First, it is limited by its retrospective nature, as a post-hoc analysis of participants enrolled in a previous study [18]. Second, we did not evaluate frailty phenotype by using physical performance-based measurements; rather, it was assessed with a self-reported questionnaire only. This may be associated with inaccuracies in frailty criteria. Third, information about dialysis adequacy or additional dialysis modalities such as hemodiafiltration or automated PD was not collected in our study. However, previous studies did not show significant differences between automated PD and continuous ambulatory PD, or between hemodiafiltration and HD [38-42]. Dialysis adequacy also influences clinical outcomes. However, Kt/V in a Korean registry was 1.55 ± 0.30 in HD patients [43]. In Korea, most patients receive adequate dialysis. In addition, BUN values were averaged using three different midweek predialysis levels. Averaged predialysis BUN is not a direct marker of dialysis adequacy, because it does not take into account protein intake and catabolism [44]. However, there may be a positive correlation between averaged predialysis BUN level and dialysis adequacy [44]. Fourth, we did not perform validations of disability and frailty questionnaires. Previous studies showed the association between disability or frailty questionnaires and clinical outcomes in various populations. However, few studies performed validation of disability and frailty questionnaires in the Korean population. Park et al. had performed validation for ADL components in the Korean elderly population, and showed their method as an acceptable tool for quantifying disability [45]. To our knowledge, there is no study involving validation of a frailty questionnaire for the Korean population. Fifth, the exclusion of patients with a history of recent hospitalization is associated with selection bias, and more HD patients than PD patients may have been excluded. The population in our study included relatively stable maintenance dialysis patients, and we did not collect data for excluded participants. However, recent hospitalization may be temporarily associated with decreased HRQoL and increased disability or frailty. These factors would result in additional bias. A future prospective multi-ethnic study that includes additional parameters such as dialysis modalities, physical performance–based measurements, or data on reliability and validity is warranted to overcome these limitations. In conclusion, there was no significant difference in frailty between patients treated with the two dialysis modalities; however, disability was more common in PD patients than in HD patients. Among the SF-36 items, MCS and PCS were more favorable in HD patients than in PD patients. Among the kidney disease-targeted scales, symptom/problems, sleep, quality of social interaction, and social support were more favorable in HD patients than in PD patients; however, patient satisfaction and dialysis staff encouragement were more favorable in PD patients than in HD patients.

Comparison of quality-of-life scores between participants receiving dialysis in a tertiary center and those receiving dialysis in a non-tertiary center.

(DOCX) Click here for additional data file.
  39 in total

1.  Comparing automated peritoneal dialysis with continuous ambulatory peritoneal dialysis: survival and quality of life differences?

Authors:  Gowrie Balasubramanian; Khadija McKitty; Stanley L-S Fan
Journal:  Nephrol Dial Transplant       Date:  2010-10-04       Impact factor: 5.992

2.  Quality of life of patients in renal replacement therapy in Brazil: comparison of treatment modalities.

Authors:  Juliana Alvares; Cibele Comini Cesar; Francisco de Assis Acurcio; Eli Iola Gurgel Andrade; Mariangela Leal Cherchiglia
Journal:  Qual Life Res       Date:  2011-09-22       Impact factor: 4.147

3.  Significance of frailty among dialysis patients.

Authors:  Kirsten L Johansen; Glenn M Chertow; Chengshi Jin; Nancy G Kutner
Journal:  J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 10.121

Review 4.  The impact of dialysis modality on quality of life: a systematic review.

Authors:  Edward Appiah Boateng; Linda East
Journal:  J Ren Care       Date:  2011-12

Review 5.  Frailty and dialysis initiation.

Authors:  Kirsten L Johansen; Cynthia Delgado; Yeran Bao; Manjula Kurella Tamura
Journal:  Semin Dial       Date:  2013-09-04       Impact factor: 3.455

6.  Quality of life in automated and continuous ambulatory peritoneal dialysis.

Authors:  Wieneke M Michels; Sandra van Dijk; Marion Verduijn; Saskia le Cessie; Elisabeth W Boeschoten; Friedo W Dekker; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2011-02-28       Impact factor: 1.756

7.  Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Antonio Alberto Lopes; Jennifer L Bragg-Gresham; Sudtida Satayathum; Keith McCullough; Trinh Pifer; David A Goodkin; Donna L Mapes; Eric W Young; Robert A Wolfe; Philip J Held; Friedrich K Port
Journal:  Am J Kidney Dis       Date:  2003-03       Impact factor: 8.860

8.  Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients.

Authors:  Edmund G Lowrie; Roberta Braun Curtin; Nancy LePain; Dorian Schatell
Journal:  Am J Kidney Dis       Date:  2003-06       Impact factor: 8.860

9.  Mortality and health-related quality of life in prevalent dialysis patients: Comparison between 12-items and 36-items short-form health survey.

Authors:  Tone Brit Hortemo Østhus; Valjbona Tiric Preljevic; Leiv Sandvik; Torbjørn Leivestad; Inger Hilde Nordhus; Toril Dammen; Ingrid Os
Journal:  Health Qual Life Outcomes       Date:  2012-05-06       Impact factor: 3.186

10.  Depressive Symptoms, Patient Satisfaction, and Quality of Life Over Time in Automated and Continuous Ambulatory Peritoneal Dialysis Patients: A Prospective Multicenter Propensity-Matched Study.

Authors:  Hee-Yeon Jung; Hye Min Jang; Yang Wook Kim; Seong Cho; Hye-Young Kim; Sung-Ho Kim; Kitae Bang; Hyun Woo Kim; So Young Lee; Sang Kyung Jo; Jonghyo Lee; Ji-Young Choi; Jang-Hee Cho; Sun-Hee Park; Chan-Duck Kim; Yong-Lim Kim
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more
  12 in total

1.  The prevalence of frailty in patients on hemodialysis: a systematic review and meta-analysis.

Authors:  Yaxi Zhao; Qinyu Liu; Jie Ji
Journal:  Int Urol Nephrol       Date:  2019-10-23       Impact factor: 2.370

Review 2.  An overview of frailty in kidney transplantation: measurement, management and future considerations.

Authors:  Meera N Harhay; Maya K Rao; Kenneth J Woodside; Kirsten L Johansen; Krista L Lentine; Stefan G Tullius; Ronald F Parsons; Tarek Alhamad; Joseph Berger; XingXing S Cheng; Jaqueline Lappin; Raymond Lynch; Sandesh Parajuli; Jane C Tan; Dorry L Segev; Bruce Kaplan; Jon Kobashigawa; Darshana M Dadhania; Mara A McAdams-DeMarco
Journal:  Nephrol Dial Transplant       Date:  2020-07-01       Impact factor: 5.992

3.  Hand grip strength measurement in haemodialysis patients: before or after the session?

Authors:  Pierre Delanaye; Kevin Quinonez; Fanny Buckinx; Jean-Marie Krzesinski; Olivier Bruyère
Journal:  Clin Kidney J       Date:  2017-12-19

4.  Use of the KDQOL-36™ for assessment of health-related quality of life among dialysis patients in the United States.

Authors:  Dena E Cohen; Andrew Lee; Scott Sibbel; Deborah Benner; Steven M Brunelli; Francesca Tentori
Journal:  BMC Nephrol       Date:  2019-04-01       Impact factor: 2.388

5.  Better Quality of Life of Peritoneal Dialysis compared to Hemodialysis over a Two-year Period after Dialysis Initiation.

Authors:  Hee-Yeon Jung; Yena Jeon; Yeongwoo Park; Yon Su Kim; Shin-Wook Kang; Chul Woo Yang; Nam-Ho Kim; Ji-Young Choi; Jang-Hee Cho; Sun-Hee Park; Chan-Duck Kim; Yong-Lim Kim
Journal:  Sci Rep       Date:  2019-07-16       Impact factor: 4.379

6.  Individualized intervention for frail non-dialysis elderly patients with chronic kidney disease: protocol for a randomized controlled trial.

Authors:  Jing Chang; Yun Gao; Xiang-Yang Fang; Su-Mei Zhao; Yuan-Ping Hou; Qian-Mei Sun
Journal:  BMC Geriatr       Date:  2020-05-04       Impact factor: 3.921

7.  Oral health-related quality of life in adult patients with end-stage kidney diseases undergoing renal replacement therapy - a systematic review.

Authors:  Gerhard Schmalz; Susann Patschan; Daniel Patschan; Dirk Ziebolz
Journal:  BMC Nephrol       Date:  2020-04-29       Impact factor: 2.388

8.  Validity and Reliability of the International Physical Activity Questionnaire in Chinese Hemodialysis Patients: A Multicenter Study in China.

Authors:  Xiaowei Lou; Qiang He
Journal:  Med Sci Monit       Date:  2019-12-10

9.  Health-Related Quality of Life in Home Dialysis Patients Compared to In-Center Hemodialysis Patients: A Systematic Review and Meta-analysis.

Authors:  Anna A Bonenkamp; Anita van Eck van der Sluijs; Tiny Hoekstra; Marianne C Verhaar; Frans J van Ittersum; Alferso C Abrahams; Brigit C van Jaarsveld
Journal:  Kidney Med       Date:  2020-02-11

Review 10.  Optimization of Dialysis Modality Transitions for Improved Patient Care.

Authors:  Benoit Imbeault; Annie-Claire Nadeau-Fredette
Journal:  Can J Kidney Health Dis       Date:  2019-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.